Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer

Detalhes bibliográficos
Autor(a) principal: Bilreiro, Carlos
Data de Publicação: 2023
Outros Autores: Andrade, Luísa, Marques, Rui Mateus, Matos, Celso
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/159823
Resumo: Publisher Copyright: © 2023, The Author(s).
id RCAP_dbcf82ceb6a1615ddc9710e3fecc59a1
oai_identifier_str oai:run.unl.pt:10362/159823
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancera systematic review and meta-analysisDiffusion magnetic resonance imagingMeta-analysisNeoadjuvant therapyPancreatic carcinomaRadiology Nuclear Medicine and imagingSDG 3 - Good Health and Well-beingPublisher Copyright: © 2023, The Author(s).Objectives: To determine the role of diffusion-weighted imaging (DWI) for predicting response to neoadjuvant therapy (NAT) in pancreatic cancer. Materials and methods: MEDLINE, EMBASE, and Cochrane Library databases were searched for studies evaluating the performance of apparent diffusion coefficient (ADC) to assess response to NAT. Data extracted included ADC pre- and post-NAT, for predicting response as defined by imaging, histopathology, or clinical reference standards. ADC values were compared with standardized mean differences. Risk of bias was assessed using the Quality Assessment of Diagnostic Studies (QUADAS-2). Results: Of 337 studies, 7 were included in the analysis (161 patients). ADC values reported for the pre- and post-NAT assessments overlapped between responders and non-responders. One study reported inability of ADC increase after NAT for distinguishing responders and non-responders. A correlation with histopathological response was reported for pre- and post-NAT ADC in 4 studies. DWI’s diagnostic performance was reported to be high in three studies, with a 91.6–100% sensitivity and 62.5–94.7% specificity. Finally, heterogeneity and high risk of bias were identified across studies, affecting the domains of patient selection, index test, reference standard, and flow and timing. Conclusion: DWI might be useful for determining response to NAT in pancreatic cancer. However, there are still too few studies on this matter, which are also heterogeneous and at high risk for bias. Further studies with standardized procedures for data acquisition and accurate reference standards are needed. Clinical relevance statement: Diffusion-weighted MRI might be useful for assessing response to neoadjuvant therapy in pancreatic cancer. However, further studies with robust data are needed to provide specific recommendations for clinical practice. Key Points: •The role of DWI with ADC measurements for assessing response to neoadjuvant therapy in pancreatic cancer is still unclear. •Pre- and post-neoadjuvant therapy ADC values overlap between responders and non-responders. •DWI has a reported high diagnostic performance for determining response when using histopathological or clinical reference standards; however, studies are still few and at high risk for bias.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNBilreiro, CarlosAndrade, LuísaMarques, Rui MateusMatos, Celso2023-11-10T22:10:28Z2023-112023-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/159823eng0938-7994PURE: 75818454https://doi.org/10.1007/s00330-023-10381-0info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:42:19Zoai:run.unl.pt:10362/159823Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:57:43.924315Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
a systematic review and meta-analysis
title Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
spellingShingle Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
Bilreiro, Carlos
Diffusion magnetic resonance imaging
Meta-analysis
Neoadjuvant therapy
Pancreatic carcinoma
Radiology Nuclear Medicine and imaging
SDG 3 - Good Health and Well-being
title_short Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
title_full Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
title_fullStr Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
title_full_unstemmed Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
title_sort Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer
author Bilreiro, Carlos
author_facet Bilreiro, Carlos
Andrade, Luísa
Marques, Rui Mateus
Matos, Celso
author_role author
author2 Andrade, Luísa
Marques, Rui Mateus
Matos, Celso
author2_role author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Bilreiro, Carlos
Andrade, Luísa
Marques, Rui Mateus
Matos, Celso
dc.subject.por.fl_str_mv Diffusion magnetic resonance imaging
Meta-analysis
Neoadjuvant therapy
Pancreatic carcinoma
Radiology Nuclear Medicine and imaging
SDG 3 - Good Health and Well-being
topic Diffusion magnetic resonance imaging
Meta-analysis
Neoadjuvant therapy
Pancreatic carcinoma
Radiology Nuclear Medicine and imaging
SDG 3 - Good Health and Well-being
description Publisher Copyright: © 2023, The Author(s).
publishDate 2023
dc.date.none.fl_str_mv 2023-11-10T22:10:28Z
2023-11
2023-11-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/159823
url http://hdl.handle.net/10362/159823
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0938-7994
PURE: 75818454
https://doi.org/10.1007/s00330-023-10381-0
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138159521431552

Registros relacionados